Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zalicus Inc.

Division of Epirus Biopharmaceuticals Inc.
www.zalicus.com

Latest From Zalicus Inc.

Epirus, Polpharma Team To Develop, Sell Rheumatoid Arthritis Biosimilars

Partners plan to bring infliximab biosimilar to market in emerging markets this year, with plans for U.S. and EU versions by 2017, then adalimumab and tocilizumab biosimilars globally in 2018 and 2019, respectively.

BioPharmaceutical Middle East and Africa

Device/Diagnostics Quarterly Deal Statistics, Q3 2014

Device financing decreased to $734 million in Q3, less than half the Q2 total, and the $4.9 billion in M&As was a sharp decline versus Q2. Diagnostics fundraising, at $399 million, showed a 31% drop from Q2, and Merck KGAA’s $16.7 billion buy of Sigma-Aldrich made up 96% of the Q3 M&A activity.

Medical Device Deals

Deals Shaping The Medical Industry, July/August 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced May and June 2014.

BioPharmaceutical Medical Device

Deals Shaping The Medical Industry, June 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced April through May 2014.

BioPharmaceutical Consumer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • CombinatoRx Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Epirus Biopharmaceuticals Inc.
  • Senior Management
  • Mark Corrigan, MD, Pres. & CEO
    Justin A Renz, EVP, CFO & Treasurer
  • Contact Info
  • Zalicus Inc.
    Phone: (617) 301-7000
    245 First St.
    3rd Floor
    Cambridge, MA 02142
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register